Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $5.7 million.

  • Corvus Pharmaceuticals' Accumulated Expenses rose 35.73% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 35.73%. This contributed to the annual value of $3.7 million for FY2024, which is 6.17% down from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Accumulated Expenses stood at $5.7 million for Q3 2025, which was up 14.12% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Accumulated Expenses registered a high of $8.6 million during Q3 2022, and its lowest value of $3.7 million during Q4 2024.
  • For the 3-year period, Corvus Pharmaceuticals' Accumulated Expenses averaged around $4.5 million, with its median value being $4.3 million (2024).
  • Per our database at Business Quant, Corvus Pharmaceuticals' Accumulated Expenses crashed by 47.40% in 2023 and then skyrocketed by 35.73% in 2025.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Accumulated Expenses stood at $7.5 million in 2022, then crashed by 47.40% to $4.0 million in 2023, then declined by 6.17% to $3.7 million in 2024, then surged by 35.73% to $5.7 million in 2025.
  • Its Accumulated Expenses stands at $5.7 million for Q3 2025, versus $5.0 million for Q2 2025 and $3.9 million for Q1 2025.